Movement Alert｜GIANT BIOGENE Falls 5.48% in Regular Trading, Interim Results Show Revenue and Net Profit Both Decline

Market Focus08-19

On August 19, GIANT BIOGENE fell 5.48% in regular trading, trading at HK$26.34/share with turnover of HK$74.04 million. The decline was triggered by the company's interim results released after market close on August 18, which showed broad-based deterioration across all key financial metrics.

The interim report revealed revenue of RMB 2.918 billion, down 6.3% year-over-year; gross profit of RMB 2.318 billion, down 8.8%; net profit attributable to equity shareholders of RMB 940 million, down 20.5%; and adjusted net profit of RMB 946 million, down 21.5%. The comprehensive earnings decline compounded existing sector concerns, as peer company S'Young Group had earlier warned of a 76.6%-78.4% mid-year profit plunge, intensifying pessimism around the personal care sector's profitability outlook.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment